Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

SARTORIUS STEDIM BIOTECH

(DIM)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sartorius Stedim Biotech : The stock approaches again the support level

share with twitter share with LinkedIn share with facebook
share via e-mail
09/11/2019 | 03:57am EDT
long trade
Live
Entry price : 129.9€ | Target : 145€ | Stop-loss : 121.8€ | Potential : 11.62%
Shares in Sartorius Stedim Biotech are retreating towards the lower bound of a horizontal trading range. Investors could use the proximity of this support area to initiate new long positions.
Investors have an opportunity to buy the stock and target the € 145.
Chart SARTORIUS STEDIM BIOTECH
Duration : Period :
Sartorius Stedim Biotech Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 122.3 support.
  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 43% by 2021.
  • The group's high margin levels account for strong profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The stock is in a well-established, long-term rising trend above the technical support level at 111.1 EUR

Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.69 times its estimated earnings per share for the ongoing year.
  • The company is not the most generous with respect to shareholders' compensation.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
Ratings chart
Subsector Medical Equipment, Supplies & Distribution - NEC
1st jan.Capitalisation (M$)Investor Rating
SARTORIUS STEDIM BIOTECH46.31%12 956
MEDTRONIC PLC19.89%147 141
BAXTER INTERNATIONAL INC.32.06%44 383
HOYA CORPORATION37.15%30 886
ZIMMER BIOMET HOLDINGS32.72%28 496
TERUMO CORP-47.51%21 925
ALIGN TECHNOLOGY-14.35%14 175
SYSMEX CORP37.91%13 995
DEXCOM, INC.24.11%13 337
STERIS PLC35.08%12 205
DENTSPLY SIRONA INC38.19%11 633
Autres valeurs du secteur

Patrick Rejaunier
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (EUR)
Sales 2019 1 396 M
EBIT 2019 349 M
Net income 2019 250 M
Debt 2019 46,1 M
Yield 2019 0,52%
P/E ratio 2019 47,0x
P/E ratio 2020 41,7x
EV / Sales2019 8,47x
EV / Sales2020 7,52x
Capitalization 11 781 M
Upcoming event on SARTORIUS STEDIM BIOTECH
09/18/19Roadshow
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 6
Average target price 134,00  €
Last Close Price 127,80  €
Spread / Highest target 15,8%
Spread / Average Target 4,85%
Spread / Lowest Target -15,5%
EPS Revisions
Managers
NameTitle
Joachim Kreuzburg Chairman, CEO, CFO & Head-Human Resources
Volker Niebel Executive VP-Operations & Information Technology
Oscar-Werner Reif Executive VP-Research & Development
Liliane de Lassus Independent Non-Executive Director
Bernard Lemaître Non-Executive Director